In AD, blocking TNF-α/IL-6 triggers compensatory upregulation of alternative inflammatory cascades (IL-1β, NLRP3) that don't exist in cardiovascular disease. This creates therapeutic resistance unique to neuroinflammation.
Curated pathway from expert analysis
flowchart TD
A["Anti-Cytokine Therapy<br/>TNF-alpha IL-6 Blockade in AD"]
B["Primary Inflammatory Cascade Reduced<br/>TNF-alpha IL-6 Signaling Attenuated"]
C["Compensatory NLRP3 Inflammasome Upregulation<br/>Alternative Inflammatory Route"]
D["IL-1beta IL-18 Increased<br/>NLRP3 Compensatory Activation"]
E["Pyroptosis in Disease-Associated Microglia<br/>Cell Death and DAMP Release"]
F["Therapeutic Resistance<br/>AD-Specific Compensatory Loops"]
G["NLRP3 Inhibitor Co-Treatment<br/>MCC950 or Dapansutrile"]
H["Dual Blockade Strategy<br/>TNF-alpha IL-6 Plus NLRP3"]
I["Neuroinflammation Resolved<br/>Synapse Protection"]
A --> B
B --> C
C --> D
D --> E
E --> F
G --> H
H --> I
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NLRP3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.